$20M in Non-Dilutive Funding Advances Breakthrough Therapies for Spinal Injury Patients
$20M
Non-dilutive funding awarded
Dignify Therapeutics was founded in 2013 to address the significant and often overlooked needs of individuals living with bladder and bowel dysfunction due to spinal cord injuries.
For more than a decade, EGC has partnered with Dignify to support the company both in securing non-dilutive funding and managing the company’s accounting and compliance needs. With EGC’s guidance, Dignify implemented a funding strategy that has resulted in over 10 years of continuous support from the NIH and DoW, totaling more than $20 million. EGC’s accounting and compliance team has also provided full-service financial management, including negotiating indirect rate agreements to ensure full recovery of overhead costs.
This combined support has been instrumental in advancing Dignify’s therapeutic pipeline from early research through clinical development. The company’s lead therapeutic, DTI-117 for on-demand bladder and bowel control, is now progressing through clinical trials—delivering a much-needed solution for patients with spinal cord injuries.
Listen to the Interview with Co-Founder Ed Burgard, Ph.D.
Eva Garland Consulting CEO, Dr. Eva Garland, speaks with Dignify Therapeutics co-founder Dr. Ed Burgard. Ed provides insight on how EGC has helped guide their non-dilutive funding approach, which started 10 years of consistent funding.
“I can’t stress enough that once you have multiple concurrent awards, you need a partner who knows the regulatory, accounting, and compliance requirements to guide you and keep you on track. Having a group like EGC at your side as you leverage non-dilutive funding to advance your science is indispensable.”
– Ed Burgard, Ph.D., Co-Founder and President, Dignify Therapeutics
Funding Sources
